About Jounce Therapeutics
Jounce Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2013, and was acquired by Concentra Biosciences in March 2023. Developer of monoclonal antibody targeting T cell Co-Stimulator. Jounce Therapeutics has raised $139 million across 4 funding rounds from investors including Celgene, Casdin Capital and Nextech Invest. The company has 137 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is JOUNCE THERAPEUTICS, INC. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Jounce Therapeutics was founded in 2013 in Cambridge, United States, as a clinical-stage immunotherapy company. Discovery and development of cancer treatments are focused on, with a pipeline emphasizing monoclonal antibodies. The lead candidate, JTX-2011, binds to Inducible T cell Co-Stimulator to activate immune responses against tumors. Studies on the tumor microenvironment, particularly tumor-associated macrophages, are conducted to advance potential immunotherapies across various cancers.
- Headquarters Cambridge, United States
- Employees 137
- Stage Acquired
- SectorsHealthcare
- Website jouncetx.com
- Social LinkedIn
- Acquired by Concentra Biosciences (Mar 2023)
- Legal Name Jounce Therapeutics, Inc.
- Total Equity Funding$139M (USD)
in 4 rounds
- Latest Funding Round$35M (USD), Post-IPO
Oct 2020
- InvestorsCelgene
& 9 more
- Employee Count137
- Acquired byConcentra Biosciences
(Mar 2023)
Funding Insights of Jounce Therapeutics
Jounce Therapeutics has successfully raised a total of $139M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $139M
- Total Rounds 4
- Last Round Post-IPO — $35M
- First Round $47M
(Feb 2013)
- Investors Count 9
All 4 funding rounds of Jounce Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $35M | Post-IPO | – | – | – |
| Jul 2016 | $36M | Series C | – | Celgene | – |
| Apr 2015 | $56M | Series B | – | – | |
| Feb 2013 | $47M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in Jounce Therapeutics
Jounce Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Celgene, Casdin Capital and Nextech Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital firm | omegafunds.com | Boston, United States | ||
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States | ||
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Venture investments in innovative pharmaceuticals, biotechnology, and medical projects worldwide. | 2010 | pharmstd.lu | Luxembourg, Luxembourg | |
Biotechnology firm involved in pharmaceutical acquisitions and industry expansions. | 2023 | concentrabiosciences.com | Canada |
Investor details for Jounce Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Jounce Therapeutics
11 people are tracked at Jounce Therapeutics (3 in leadership, 7 in board & advisors, 1 in team); the tracked headcount is 137.
| Name | Role | Group |
|---|---|---|
Carlos C da Camara | Sr Director, Senior Medical Science Liaison | Leadership |
Di Li | Vice President, Biostatistics And Programming | Leadership |
Keith Barnett | Senior Director, Head of Clinical Operations | Leadership |
James P. Allison | Founder | Board & advisors |
Thomas F. Gajewski | Founder | Board & advisors |
Louis M. Weiner | Founder | Board & advisors |
Padmanee Sharma | Founder | Board & advisors |
Drew Pardoll | Founder | Board & advisors |
Robert Schreiber | Founder | Board & advisors |
Luis A. Diaz | Director | Board & advisors |
Liddy Kasraian | Clinical Operations Associate | Team |
Complete people profiles for Jounce Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Jounce Therapeutics
5 dated milestones of Jounce Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Jounce Therapeutics is founded.
- Funding First funding round of $47.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $35.0M.
- Exit Acquired by Concentra Biosciences.
Competitors of Jounce Therapeutics
Jounce Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Jounce Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Jounce Therapeutics
Websites that share an audience with Jounce Therapeutics (jouncetx.com).
Websites whose visitors overlap most with Jounce Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| exosomedx.com | 100% | 9.4K | #2,686,224 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Jounce Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jounce Therapeutics
Complete news archive for Jounce Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jounce Therapeutics
Jounce Therapeutics was founded in 2013.
Jounce Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Jounce Therapeutics is a funded company, having raised a total of $139M across 4 funding rounds to date. The company's 1st funding round was a Series A of $47M, raised on Feb 2013.
Jounce Therapeutics has 137 employees.
Jounce Therapeutics was founded in 2013 in Cambridge, United States, as a clinical-stage immunotherapy company. Discovery and development of cancer treatments are focused on, with a pipeline emphasizing monoclonal antibodies. The lead candidate, JTX-2011, binds to Inducible T cell Co-Stimulator to activate immune responses against tumors. Studies on the tumor microenvironment, particularly tumor-associated macrophages, are conducted to advance potential immunotherapies across various cancers.
Jounce Therapeutics's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Jounce Therapeutics has 10 investors. Key investors include Celgene, Casdin Capital, Nextech Invest, Wellington, and Foresite Capital.
Jounce Therapeutics operates through Jounce Therapeutics, Inc..
Yes. Jounce Therapeutics was acquired by Concentra Biosciences in March 2023.